Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
16,121 stopped studies · 89% state a reason
Over the 16,121 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02432378 | Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC… | Phase 1 / Phase 2 | withdrawn | May 4, 2015 | Roswell Park Cancer Institute | opening up at a different site | Other (stated, no rule matched) |
| NCT04527900 | The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach | Phase 2 | terminated | Aug 27, 2020 | University of Maryland, Baltimore | SOC changed and low enrollment | Enrollment / accrual |
| NCT05705791 | Clinical Investigation Evaluating Safety and Efficacy of Selective Intra-arterial…(HOLMBRAVE) | N/A | terminated | Jan 31, 2023 | Gustave Roussy, Cancer Campus, Grand Paris | Toxicities | Safety / toxicity |
| NCT05891847 | Non-interventional Study of Patients With PN NF1 Starting Selumetinib in Russia | — | terminated | Jun 7, 2023 | AstraZeneca | Statistically significant failure to achieve key secondary endpoints. The current data do not… | Sponsor / business decision |
| NCT06585488 | A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in… | Phase 1 | terminated | Sep 5, 2024 | BeOne Medicines | The Sponsor has made the decision to terminate this study due to the lack of promising efficacy,… | Efficacy / futility |
| NCT00640978 | Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic… | Phase 2 | terminated | Mar 21, 2008 | M.D. Anderson Cancer Center | Significant Adverse Effects - Futility | Safety / toxicity |
| NCT04216472 | Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple… | Phase 2 | terminated | Jan 2, 2020 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT04585477 | Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E) | Phase 2 | suspended | Oct 14, 2020 | Stanford University | pending protocol amendment | Other (stated, no rule matched) |
| NCT04824859 | A Geriatric Assessment Electronic Platform for Older Patients With Cancer (eGAP -…(eGAP) | N/A | terminated | Apr 1, 2021 | University of Rochester | Technology issues | Other (stated, no rule matched) |
| NCT05109494 | Hypofractionated vs Conventional Fractionated RT in Soft Tissue Sarcomas | Phase 2 | suspended | Nov 5, 2021 | University of Wisconsin, Madison | Administrative | Other (stated, no rule matched) |
| NCT05164666 | A Study of TAK-103 in Adult With Solid Tumors | Phase 1 | terminated | Dec 21, 2021 | Takeda | Business decision unrelated to patient safety | Safety / toxicity |
| NCT05220098 | First-in-Human Study of TAK-280 in Participants With Solid Tumors | Phase 1 / Phase 2 | terminated | Feb 2, 2022 | Takeda | Terminated due to limited anti-cancer activity | Other (stated, no rule matched) |
| NCT06466187 | A Study of SGN-MesoC2 in Advanced Solid Tumors | Phase 1 | terminated | Jun 20, 2024 | Seagen, a wholly owned subsidiary of Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety concerns | Safety / toxicity |
| NCT07176975 | A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1… | Phase 1 | suspended | Sep 16, 2025 | Boehringer Ingelheim | company decision | Sponsor / business decision |
| NCT04037527 | Gemcitabine and Docetaxel With Radiation in Adults With Soft Tissue Sarcoma of the… | Phase 1 | terminated | Jul 30, 2019 | Wake Forest University Health Sciences | Terminated due DLTs | Other (stated, no rule matched) |
| NCT05086315 | First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult… | Phase 1 / Phase 2 | terminated | Oct 20, 2021 | Sanofi | Early discontinuation based on strategic sponsor decision not driven by any safety concerns. | Safety / toxicity |
| NCT05422105 | Diagnostic Performance of 18F-PSMA-1007 PET/CT in Suspected Prostate Cancer Patient | — | suspended | Jun 16, 2022 | Primo Biotechnology Co., Ltd | Interim Analysis | Efficacy / futility |
| NCT05731947 | Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors | Phase 1 / Phase 2 | terminated | Feb 16, 2023 | Syndax Pharmaceuticals | Study was terminated by sponsor after Phase 1b as pre-defined signals of efficacy were not met in… | Efficacy / futility |
| NCT06120504 | A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers | Phase 1 | terminated | Nov 7, 2023 | Seagen, a wholly owned subsidiary of Pfizer | Study terminated as part of strategic considerations | Sponsor / business decision |
| NCT06254495 | A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers | Phase 1 | terminated | Feb 12, 2024 | Seagen, a wholly owned subsidiary of Pfizer | The trial was terminated for strategic reasons due to portfolio reprioritization. The decision was… | Safety / toxicity |
| NCT06922604 | Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System… | Phase 1 | suspended | Apr 10, 2025 | City of Hope Medical Center | Pending Amendment Approval | Other (stated, no rule matched) |
| NCT07084584 | ENLIGHT-AML - An Open-label, Study of GB3226 in Patients With Relapsed/Refractory Acute… | Phase 1 | withdrawn | Jul 24, 2025 | Galecto Biotech AB | Study withdrawn due to business priority changes | Sponsor / business decision |
| NCT07558330 | Evaluation of the Clinical Impact of the Numerique Medical Device MAELA® Ont the Care…(CODAP) | N/A | withdrawn | Apr 30, 2026 | Assistance Publique - Hôpitaux de Paris | Inability to complete the study within the alloted time | Other (stated, no rule matched) |
| NCT04809766 | Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic… | Phase 1 | terminated | Mar 22, 2021 | Fred Hutchinson Cancer Center | Study terminated due to end of funding. | Funding |
| NCT05525247 | A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010… | Phase 1 / Phase 2 | terminated | Sep 1, 2022 | Selecxine | Business decision | Sponsor / business decision |
| NCT05606315 | RemImazolam Besylate for ICU-sedation in Patients With Mechanical Ventilation After Oral… | Phase 4 | terminated | Nov 4, 2022 | Nanfang Hospital, Southern Medical University | The trial was terminated early because additional sites did not recruit as planned, making the… | Safety / toxicity |
| NCT05660967 | Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse…(EPCORE DLBCL-3) | Phase 2 | terminated | Dec 21, 2022 | Genmab | The study was terminated because sufficient data had been collected to meet the objectives of the… | Safety / toxicity |
| NCT05797870 | Selective Internal Radiation Therapy and 188Re-SSS Lipiodol Treatment for Liver Cancer…(Lip-Re2) | Phase 2 | terminated | Apr 4, 2023 | Center Eugene Marquis | The last visit of the last patient was done. | Other (stated, no rule matched) |
| NCT07369791 | Nivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced…(NOBLE) | Phase 2 | withdrawn | Jan 27, 2026 | National Health Research Institutes, Taiwan | The study was terminated due to administrative reasons following the cancellation of collaboration… | Other (stated, no rule matched) |
| NCT01871571 | Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating… | Phase 2 | terminated | Jun 6, 2013 | University of Southern California | Insufficient Accrual | Enrollment / accrual |
| NCT02829736 | ThOracoscopic Wedge Resection Treated With Chest Tube Removal Intraoperatively(TOTTI) | N/A | terminated | Jul 12, 2016 | Rigshospitalet, Denmark | Slow accrual | Enrollment / accrual |
| NCT03710421 | CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory… | Phase 1 | suspended | Oct 18, 2018 | City of Hope Medical Center | Slow/Low Accrual | Enrollment / accrual |
| NCT04273555 | Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients… | Phase 1 / Phase 2 | withdrawn | Feb 18, 2020 | University of Alabama at Birmingham | Unable to recruit for this study. | Enrollment / accrual |
| NCT05571839 | A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors | Phase 1 | terminated | Oct 7, 2022 | Seagen, a wholly owned subsidiary of Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety concerns. | Safety / toxicity |
| NCT05967533 | The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With… | Phase 1 | suspended | Aug 1, 2023 | University of California, Davis | For internal interim analysis | Efficacy / futility |
| NCT06455189 | Magnetic Resonance Fingerprinting Guided Extended Resection in Glioblastomas | Phase 1 | withdrawn | Jun 12, 2024 | Case Comprehensive Cancer Center | Terminated IRB | Other (stated, no rule matched) |
| NCT07045727 | Prehabilitation With Aerobic and Resistance Exercise for Improving Physical Fitness and… | N/A | terminated | Jul 1, 2025 | Mayo Clinic | Limited funding, slow accrual | Enrollment / accrual |
| NCT00006344 | Radiation Therapy in Preventing Brain Metastases in Patients With Small Cell Lung Cancer | Phase 3 | withdrawn | May 24, 2004 | Virginia Commonwealth University | PI left institution | Investigator |
| NCT04751383 | Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in… | Phase 1 | terminated | Feb 12, 2021 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
| NCT04788043 | Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma | Phase 2 | terminated | Mar 9, 2021 | Ranjana Advani | Discontinuation of magrolimab development | Other (stated, no rule matched) |
| NCT04887935 | Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer | Phase 1 | terminated | May 14, 2021 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT06169280 | Repeated Neural Stem Cell Based Virotherapy for Newly Diagnosed High Grade Glioma | Phase 1 | suspended | Dec 13, 2023 | Northwestern University | Safety issues | Safety / toxicity |
| NCT06561425 | A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With…(Atalanta-1) | Phase 1 / Phase 2 | terminated | Aug 20, 2024 | Lakefront Biotherapeutics NV | Following the decision by Galapagos NV to wind down its cell therapy programs, the study was early… | Other (stated, no rule matched) |
| NCT03919292 | Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca | Phase 1 / Phase 2 | suspended | Apr 18, 2019 | Virginia Commonwealth University | Pending amendment approval | Other (stated, no rule matched) |
| NCT04412135 | The Point of View of Hematological Cancer Patients and Their Loved Ones Regarding…(SPIRIHEMATO) | — | withdrawn | Jun 2, 2020 | University Hospital, Limoges | Sponsor decision | Sponsor / business decision |
| NCT04926324 | A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers | Phase 1 | terminated | Jun 15, 2021 | University of Iowa | Toxicity in phase 1 | Safety / toxicity |
| NCT05101356 | A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab… | Phase 1 / Phase 2 | suspended | Nov 1, 2021 | University of California, Davis | Drugs unavailable | Other (stated, no rule matched) |
| NCT05204290 | Study of Combined Decompressive Spine Radiosurgery and Pembrolizumab | Early Phase 1 | terminated | Jan 24, 2022 | Wake Forest University Health Sciences | Low accruals | Enrollment / accrual |
| NCT05627323 | CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma | Phase 1 | terminated | Nov 25, 2022 | Chimeric Therapeutics | IND application withdrawn | Other (stated, no rule matched) |
| NCT06191250 | --SuPERIOR Trial-- | Phase 2 | terminated | Jan 5, 2024 | University Health Network, Toronto | Study Terminated Prior to trial activation, due to changes in SOC of the treatment | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jul 8, 2026source: clinicaltrials